AdAPT-001
2 abstracts
Abstract
Phase 1/2 study of the TGF-β-trap-enhanced oncolytic adenovirus, AdAPT-001, plus an immune checkpoint inhibitor for patients with immune refractory cancers.Org: EpicentRx, Clinical Trials Innovations, Cleveland Clinic Lerner College of Medicine,
Abstract
Initial results from a first in human dose escalation trial of a novel immune stimulating oncolytic adenovirus, AdAPT-001TGF-ß Trap.Org: University of Texas MD Anderson Cancer Center, The Cleveland Clinic Foundation, City of Hope National Medical Center, EpicentRx, Mary Crowley Cancer Research Center,